The
tumor suppressor
15-hydroxyprostaglandin dehydrogenase (15-PGDH) is the key
enzyme in
prostaglandin E2 catabolism and is down-regulated in
colorectal cancer (CRC) tissue. Canonical Wnt signaling is frequently elevated in
colon cancers and has been shown to down-regulate
15-PGDH expression. Therefore, we have in the current study investigated if the non-canonical
ligand WNT5A relates to increased expression of
15-PGDH in
colon cancer cells. In the same cohort of patients, we demonstrated a parallel and significant loss of
15-PGDH and
WNT5A protein expression in CRC tissues compared with matched normal colon tissues. Furthermore, patients with low 15-PGDH/WNT5A expression in their
tumors showed reduced survival compared with patients with high 15-PGDH/WNT5A expression. To investigate if WNT5A signaling directly affects
15-PGDH expression, we performed in vitro analyses of
colon cancer cells (HT-29 and Caco-2). Both cell lines, when treated with recombinant WNT5A (rWNT5A) or Foxy-5, a WNT5A-mimicking
peptide, responded by increasing their expression of
15-PGDH mRNA and
protein. Our investigations showed that rWNT5A and Foxy-5 induced this increased expression of
15-PGDH through reduced β-
catenin signaling as well as increased JNK/AP-1 signaling in
colon cancer cells. WNT5A signaling also induced increased
15-PGDH expression in a
breast cancer cell line both in vitro and in vivo. In agreement, WNT5A signaling also increased the expression of the
differentiation markers sucrose-
isomaltase and
mucin-2 in
colon cancer cells. Our results show that WNT5A signaling regulates
15-PGDH expression, thus uncovering a novel mechanism by which WNT5A acts as a
tumor suppressor and suggests that increased
15-PGDH expression could be used as an
indicator of a positive response to Foxy-5 in patients treated with this WNT5A agonist.